Maze chief business officer sells 7,500 shares
Maze Therapeutics, Inc. (MAZE) officer Atul Dandekar (CSBO) reported an option exercise and same-day sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics, Inc. (MAZE) officer Atul Dandekar (CSBO) reported an option exercise and same-day sale. On 2026-08-28, he exercised 7,500 stock options for common stock at an exercise price of $10.42 per share, receiving 7,500 shares, then sold 7,500 common shares at a weighted average price of $27.5765 per share in transactions ranging from $27.31 to $28.01. The option, which became fully vested on March 17, 2025, now has 14,143 options reported as remaining and expires on 2031-04-11. All reported trades were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($129K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Dandekar Atul
Role
CSBO
Sold
7,500 shs ($207K)
Approx. gross sale proceeds
$207K
Approx. exercise cost
$78K
Approx. pre-tax spread
$129K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,500 | $10.42 | $78K |
| Sale | Common Stock F1, F2 | 7,500 | $27.5765 | $207K |
Holdings After Transaction:
Stock Option (Right to Buy) — 14,143 contracts (Direct);
Common Stock — 26,250 shares (Direct)
Footnotes (3)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $28.01 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
Key Figures
Options Exercised: 7,500 shares
Option Exercise Price: $10.42 per share
Shares Sold: 7,500 shares
+5 more
8 metrics
Options Exercised
7,500 shares
Stock Option (Right to Buy) exercised on 2026-08-28
Option Exercise Price
$10.42 per share
Exercise price for 7,500 Maze Therapeutics, Inc. options
Shares Sold
7,500 shares
Common stock sale on 2026-08-28 following option exercise
Weighted Average Sale Price
$27.5765 per share
Weighted average price for 7,500 MAZE shares sold
Sale Price Range
$27.31–$28.01 per share
Range of prices for multiple sale transactions
Remaining Options
14,143 options
Total shares underlying options held after the transaction
Option Expiration Date
2031-04-11
Expiration of the exercised stock option award
10b5-1 Plan Adoption Date
September 29, 2025
Date Atul Dandekar adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy, weighted average price, derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)"
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MAZE officer Atul Dandekar report in this Form 4?
He reported exercising 7,500 stock options for Maze Therapeutics, Inc. common stock at an exercise price of $10.42 per share and selling 7,500 shares of common stock at a weighted average price of $27.5765 per share on 2026-08-28.
Were the MAZE trades by Atul Dandekar under a Rule 10b5-1 plan?
Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Atul Dandekar on September 29, 2025, indicating the trades followed a pre-arranged plan.
How many Maze Therapeutics options does Atul Dandekar report remaining after this transaction?
Following the reported option exercise, Atul Dandekar reports 14,143 stock options remaining for Maze Therapeutics, Inc. common stock under the exercised award, which expires on April 11, 2031.
When did the MAZE stock option exercised by Dandekar become fully vested?
The Form 4 discloses that the stock option award became fully vested on March 17, 2025, pursuant to the terms of Atul Dandekar’s award agreement with Maze Therapeutics, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
